These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 23770297)
21. Molecular Characteristics of IS Zhi Y; Ji HJ; Jung JH; Byun EB; Kim WS; Lin SM; Lim S; Jang AY; Choi MJ; Ahn KB; Lim JH; Song JY; Seo HS mSphere; 2021 Aug; 6(4):e0054321. PubMed ID: 34319128 [TBL] [Abstract][Full Text] [Related]
22. The Abi-domain protein Abx1 interacts with the CovS histidine kinase to control virulence gene expression in group B Streptococcus. Firon A; Tazi A; Da Cunha V; Brinster S; Sauvage E; Dramsi S; Golenbock DT; Glaser P; Poyart C; Trieu-Cuot P PLoS Pathog; 2013 Feb; 9(2):e1003179. PubMed ID: 23436996 [TBL] [Abstract][Full Text] [Related]
23. Streptococcus agalactiae capsule polymer length and attachment is determined by the proteins CpsABCD. Toniolo C; Balducci E; Romano MR; Proietti D; Ferlenghi I; Grandi G; Berti F; Ros IM; Janulczyk R J Biol Chem; 2015 Apr; 290(15):9521-32. PubMed ID: 25666613 [TBL] [Abstract][Full Text] [Related]
24. Surface Structures of Group B Paoletti LC; Kasper DL Microbiol Spectr; 2019 Mar; 7(2):. PubMed ID: 30873933 [TBL] [Abstract][Full Text] [Related]
25. Identification of immunoreactive proteins of Streptococcus agalactiae isolated from cultured tilapia in China. Liu G; Zhang W; Lu C Pathog Dis; 2013 Dec; 69(3):223-31. PubMed ID: 23929656 [TBL] [Abstract][Full Text] [Related]
26. Variation in the group B Streptococcus CsrRS regulon and effects on pathogenicity. Jiang SM; Ishmael N; Dunning Hotopp J; Puliti M; Tissi L; Kumar N; Cieslewicz MJ; Tettelin H; Wessels MR J Bacteriol; 2008 Mar; 190(6):1956-65. PubMed ID: 18203834 [TBL] [Abstract][Full Text] [Related]
27. Identification of Zinc-Dependent Mechanisms Used by Group B Burcham LR; Le Breton Y; Radin JN; Spencer BL; Deng L; Hiron A; Ransom MR; Mendonça JDC; Belew AT; El-Sayed NM; McIver KS; Kehl-Fie TE; Doran KS mBio; 2020 Nov; 11(6):. PubMed ID: 33173000 [TBL] [Abstract][Full Text] [Related]
28. A cytosol derived factor of Group B streptococcus prevent its invasion into human epithelial cells. Ohri M; Parashar S; Pai VS; Ghosh S; Chakraborti A World J Microbiol Biotechnol; 2018 Mar; 34(3):45. PubMed ID: 29520519 [TBL] [Abstract][Full Text] [Related]
29. Immunogenicity of amino acids 1-150 of Streptococcus GapC displayed on the surface of Escherichia coli. Song B; Yang X; Sun H; Yu L; Ma J; Wu Z; Cui Y Microb Pathog; 2017 Apr; 105():288-297. PubMed ID: 28179116 [TBL] [Abstract][Full Text] [Related]
30. CovS/CovR of group B streptococcus: a two-component global regulatory system involved in virulence. Lamy MC; Zouine M; Fert J; Vergassola M; Couve E; Pellegrini E; Glaser P; Kunst F; Msadek T; Trieu-Cuot P; Poyart C Mol Microbiol; 2004 Dec; 54(5):1250-68. PubMed ID: 15554966 [TBL] [Abstract][Full Text] [Related]
31. Comparison of virulence factors and capsular types of Streptococcus agalactiae isolated from human and bovine infections. Emaneini M; Khoramian B; Jabalameli F; Abani S; Dabiri H; Beigverdi R Microb Pathog; 2016 Feb; 91():1-4. PubMed ID: 26593104 [TBL] [Abstract][Full Text] [Related]
32. Putative lipoproteins of Streptococcus agalactiae identified by bioinformatic genome analysis. Sutcliffe IC; Harrington DJ Antonie Van Leeuwenhoek; 2004 May; 85(4):305-15. PubMed ID: 15028868 [TBL] [Abstract][Full Text] [Related]
33. Regulation of CovR expression in Group B Streptococcus impacts blood-brain barrier penetration. Lembo A; Gurney MA; Burnside K; Banerjee A; de los Reyes M; Connelly JE; Lin WJ; Jewell KA; Vo A; Renken CW; Doran KS; Rajagopal L Mol Microbiol; 2010 Jul; 77(2):431-43. PubMed ID: 20497331 [TBL] [Abstract][Full Text] [Related]
34. Characterization of a novel leucine-rich repeat protein antigen from group B streptococci that elicits protective immunity. Seepersaud R; Hanniffy SB; Mayne P; Sizer P; Le Page R; Wells JM Infect Immun; 2005 Mar; 73(3):1671-83. PubMed ID: 15731068 [TBL] [Abstract][Full Text] [Related]
35. [Recombinant fragments of conservative proteins of group B streptococci as a basis of specific vaccine]. Suvorov AN; Grabovskaia KB; Leont'eva GF; Meringova LF; Koroleva IN; Duplik NV; Totolian AA Zh Mikrobiol Epidemiol Immunobiol; 2010; (2):44-50. PubMed ID: 20465000 [TBL] [Abstract][Full Text] [Related]
36. The Streptococcus agalactiae complement interfering protein combines multiple complement-inhibitory mechanisms by interacting with both C4 and C3 ligands. Giussani S; Pietrocola G; Donnarumma D; Norais N; Speziale P; Fabbrini M; Margarit I FASEB J; 2019 Mar; 33(3):4448-4457. PubMed ID: 30566365 [TBL] [Abstract][Full Text] [Related]
37. Variability in the distribution of genes encoding virulence factors and putative extracellular proteins of Streptococcus pyogenes in India, a region with high streptococcal disease burden, and implication for development of a regional multisubunit vaccine. Sagar V; Bergmann R; Nerlich A; McMillan DJ; Nitsche Schmitz DP; Chhatwal GS Clin Vaccine Immunol; 2012 Nov; 19(11):1818-25. PubMed ID: 22971782 [TBL] [Abstract][Full Text] [Related]
38. Group B Streptococcal Toxic Shock Syndrome and covR/S Mutations Revisited. Sendi P; El Hay MA; Brandt CM; Spellerberg B Emerg Infect Dis; 2017 Jan; 23(1):150-152. PubMed ID: 27983484 [TBL] [Abstract][Full Text] [Related]
39. Molecular Evolution of Clinical Pathogenic Streptococci. Li D; Tao C Curr Issues Mol Biol; 2019; 32():561-600. PubMed ID: 31166180 [TBL] [Abstract][Full Text] [Related]
40. Identification of a glycosaminoglycan binding region of the alpha C protein that mediates entry of group B Streptococci into host cells. Baron MJ; Filman DJ; Prophete GA; Hogle JM; Madoff LC J Biol Chem; 2007 Apr; 282(14):10526-36. PubMed ID: 17259175 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]